---
title: "Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis"
id: "medrxiv-21-hormone-replacement-therapy-and-disability-progression-in-women-with-multiple"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-hormone-replacement-therapy-and-disability-progression-in-women-with-multiple"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.21.26366096v1?rss=1"
published_at: "2026-10-23T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-hormone-replacement-therapy-and-disability-progression-in-women-with-multiple
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.21.26366096v1?rss=1)
- **Published At:** 2026-10-23T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators used a nationwide Swedish registry cohort to examine systemic **HRT** and disability in women with **Multiple Sclerosis**; entry spanned 2006–2024 with follow-up through 2025. - The cohort included 7,623 women aged 40–60 at entry; 1,192 (15.6%) initiated HRT under a new-user design. - Exposure was modeled as time-varying current use and quarterly oral-equivalent dose categories; the source did not report specific formulations or regimens. - Primary outcomes were sustained **EDSS** 4.0 and sustained **EDSS** 6.0; a secondary outcome was recurring relapses. - Cox models adjusted for baseline covariates and time-varying age and disease-modifying therapy (DMT) class. - Current HRT use was associated with lower hazard for sustained EDSS 4.0 (aHR 0.70, 95% CI 0.51–0.96). - No statistically significant association was observed for sustained EDSS 6.0 (aHR 0.80, 95% CI 0.55–1.16). - Recurring relapse risk was neutral with HRT (aHR 1.00, 95% CI 0.74–1.36). - Dose categories did not reveal a consistent gradient in outcomes; the report did not provide dose-specific absolute event counts. - A sensitivity analysis raising cohort-entry age to 50 years produced a similar EDSS 4.0 estimate (aHR 0.62, 95% CI 0.40–0.95). - Menopausal status was unmeasured in the registries; the authors called for replication in cohorts with verified menopausal status for clinical interpretation. - Ethical approvals were granted by the Regional Ethical Review Board in Stockholm and the Swedish Ethical Review Authority; individual consent was waived for pseudonymized registry data. - The study protocol was not registered and individual-level registry data cannot be shared publicly under Swedish law; code is available on request from the corresponding author.
## Clinical Analysis & Structured Key Points
Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis | medRxiv Skip to main content Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis View ORCID Profile Timothy P Copeland , View ORCID Profile Kyla A McKay , View ORCID Profile Astrid Pedersen , Roxane Handal-Orefice , View ORCID Profile Katharina Fink doi: https://doi.org/10.64898/2026.10.21.26366096 Timothy P Copeland 1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Timothy P Copeland For correspondence: copeland.tim{at}gmail.com Kyla A McKay 2 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kyla A McKay Astrid Pedersen 1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Astrid Pedersen Roxane Handal-Orefice 3 Arrowhead Regional Medical Center, Colton, California, United States Find this author on Google Scholar Find this author on PubMed Search for this author on this site Katharina Fink 2 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Katharina Fink Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Evidence on menopausal hormone replacement therapy (HRT) and disability progression in women with multiple sclerosis (MS) is limited, particularly in the era of high-efficacy disease-modifying therapy. We estimated the association between systemic HRT and sustained disability progression and recurring relapses in a contemporary national cohort. Methods: In a nationwide Swedish registry-based cohort, we followed women with MS aged 40 to 60 years entering from 2006 through 2024, with follow-up through 2025, under a new-user design. Systemic HRT was modeled as time-varying current use and quarterly oral-equivalent dose categories. Outcomes were sustained Expanded Disability Status Scale (EDSS) 4.0, sustained EDSS 6.0, and recurring relapses. Cox models adjusted for baseline covariates and time-varying age and disease-modifying therapy (DMT) class. Results: Among 7,623 women, 1,192 (15.6%) initiated HRT. Current HRT use was associated with a lower hazard of sustained EDSS 4.0 (adjusted hazard ratio [aHR] 0.70, 95% confidence interval [CI] 0.51 to 0.96) but not sustained EDSS 6.0 (aHR 0.80, 95% CI 0.55 to 1.16) or recurring relapses (aHR 1.00, 95% CI 0.74 to 1.36). Dose categories showed no consistent gradient. Raising the cohort-entry age floor to 50 years gave a consistent EDSS 4.0 estimate (aHR 0.62, 95% CI 0.40 to 0.95). Conclusions: HRT was not associated with increased relapse risk or severe disability progression. The lower hazard of sustained EDSS 4.0 was not mirrored at EDSS 6.0 and showed no dose gradient. Given menopausal status was unmeasured, replication in cohorts with verified menopausal status is required for clear clinical interpretation. Competing Interest Statement TPC, AP, and RHO report no competing interests. KAM receives research funding from the Swedish Research Council and ALF Medicine and has received speaker honoraria from Biogen (2022) and Sanofi-Aventis (2023). KF has served on scientific advisory boards for Alexion, Biogen, Janssen, Merck, Novartis, Takeda and Roche, and has received financial research support from Merck and Amicus. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Regional Ethical Review Board in Stockholm approved the study (2017/700-31/4), and the Swedish Ethical Review Authority approved an amendment (2021-02384). Individual informed consent was waived because the study used pseudonymized registry data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Individual-level data from the Swedish registries cannot be shared publicly due to Swedish law. Researchers may apply for data access through Statistics Sweden (SCB) and the Swedish National Board of Health and Welfare (Socialstyrelsen). Access to the Swedish MS Registry requires a separate application to the registry holder. Analysis code is available from the corresponding author upon reasonable request. No study protocol was registered. Funder Information Declared Swedish Research Council , 2023-02567 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 23, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis Timothy P Copeland , Kyla A McKay , Astrid Pedersen , Roxane Handal-Orefice , Katharina Fink medRxiv 2026.10.21.26366096; doi: https://doi.org/10.64898/2026.10.21.26366096 Share This Article: Copy Citation Tools Hormone Replacement Therapy and Disability Progression in Women with Multiple Sclerosis Timothy P Copeland , Kyla A McKay , Astrid Pedersen , Roxane Handal-Orefice , Katharina Fink medRxiv 2026.10.21.26366096; doi: https://doi.org/10.64898/2026.10.21.26366096 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (633) Allergy and Immunology (914) Anesthesia (345) Cardiovascular Medicine (4943) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (671) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1667) Epidemiology (16161) Forensic Medicine (35) Gastroenterology (1236) Genetic and Genomic Medicine (7209) Geriatric Medicine (747) Health Economics (1091) Health Informatics (5222) Health Policy (1456) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16426) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (739) Neurology (7497) Nursing (375) Nutrition (1114) Obstetrics and Gynecology (1281) Occupational and Environmental Health (1031) Oncology (3708) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (493) Palliative Medicine (142) Pathology (717) Pediatrics (1844) Pharmacology and Therapeutics (749) Primary Care Research (781) Psychiatry and Clinical Psychology (6065) Public and Global Health (9915) Radiology and Imaging (2499) Rehabilitation Medicine and Physical Therapy (1499) Respiratory Medicine (1263) Rheumatology (655) Sexual and Reproductive Health (794) Sports Medicine (594) Surgery (795) Toxicology (109) Transplantation (315) Urology (303)
## Related Clinical Research

- [Understanding the Complexity of Multiple Sclerosis Diagnosis: Lessons from Christina Applegate](https://medichelpline.com/clinical-feed/stat-news-0-opinion-christina-applegate-puts-a-face-on-one-of-the-most-consequential.md)
- [Patient death reported in Bristol Myers Squibb CAR-T trial for multiple sclerosis](https://medichelpline.com/clinical-feed/stat-news-2-stat-patient-dies-in-bristol-myers-squibb-autoimmune-car-t-trial.md)
- [Live Birth Rates in Swedish Women with Multiple Sclerosis, 2004–2022](https://medichelpline.com/clinical-feed/medrxiv-20-live-birth-rates-among-women-with-multiple-sclerosis-in-sweden-2004-to-2022-a.md)
- [Testing frequency explains most SDMT differences between natalizumab and rituximab in Swedish MS r](https://medichelpline.com/clinical-feed/medrxiv-22-more-tests-higher-scores-testing-frequency-and-sdmt-differences-between.md)
- [Ultra-processed foods linked to MRI signs of vascular brain injury in middle-aged adults](https://medichelpline.com/clinical-feed/medical-news-today-0-ultra-processed-foods-may-be-harming-brain-health-in-otherwise-healthy-adults.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.